|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.00 EUR | -2.12% |
|
-1.60% | -9.31% |
| 06-17 | European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading | MT |
| 06-17 | Medpace: At the Heart of the Small-Cap Biopharma Crisis |  |
| Market Cap | 89.87B 104B 82.63B 77.77B 146B 9,831B 147B 979B 381B 4,825B 391B 383B 16,692B | P/E 2026 * |
11.1x | P/E 2027 * | 10.4x |
|---|---|---|---|---|---|
| Enterprise Value | 101B 117B 92.56B 87.12B 164B 11,013B 165B 1,097B 427B 5,405B 438B 429B 18,699B | EV / Sales 2026 * |
2.14x | EV / Sales 2027 * | 1.96x |
| Free-Float |
89% | Yield 2026 * |
5.68% | Yield 2027 * | 6.02% |
Last Transcript: Sanofi
| 1 week | -1.60% | ||
| Current month | -1.07% | ||
| 1 month | +1.09% | ||
| 3 months | -3.14% | ||
| 6 months | -7.96% | ||
| Current year | -9.31% |
| 1 week | 36.8 |  | 38.4 |
| 1 month | 36.4 | | 39 |
| 3 years | 36 | | 55 |
| 5 years | 36 | | 55 |
| 10 years | 30.6 | | 55 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 01/05/2026 | |
| Director of Finance/CFO | 64 | 01/04/2024 | |
Houman Ashrafian
CTO | Chief Tech/Sci/R&D Officer | 51 | 11/09/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 60 | 30/04/2019 | |
Rachel Duan
BRD | Director/Board Member | 56 | 28/04/2020 |
Lise Kingo
BRD | Director/Board Member | 64 | 28/04/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.12% | -1.60% | -12.32% | -21.94% | 105B | |
| -0.94% | -2.14% | +40.54% | +148.38% | 1,001B | |
| -0.42% | -1.80% | +53.69% | +42.60% | 566B | |
| -0.56% | -1.65% | +19.27% | +59.57% | 393B | |
| -1.18% | +0.68% | +24.66% | +16.53% | 326B | |
| +1.42% | +0.06% | +26.36% | +14.29% | 277B | |
| +1.09% | +1.65% | +26.61% | +33.32% | 276B | |
| +1.87% | +0.87% | -41.49% | -48.26% | 193B | |
| -1.78% | +1.16% | +17.79% | +48.77% | 188B | |
| -1.40% | +3.27% | +16.16% | +59.08% | 158B | |
| Average | -0.21% | +0.41% | +17.13% | +35.23% | 375.2B | |
| Weighted average by Cap. | -0.38% | -0.50% | +28.09% | +63.60% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 47.07B 54.56B 43.27B 40.73B 76.54B 5,149B 77.18B 513B 200B 2,527B 205B 200B 8,742B | 49.98B 57.93B 45.95B 43.25B 81.27B 5,467B 81.95B 545B 212B 2,683B 217B 213B 9,283B |
| Net income | 8.15B 9.44B 7.49B 7.05B 13.24B 891B 13.36B 88.74B 34.55B 437B 35.44B 34.68B 1,513B | 8.95B 10.38B 8.23B 7.75B 14.56B 980B 14.68B 97.56B 37.98B 481B 38.96B 38.13B 1,663B |
| Net Debt | 10.8B 12.52B 9.93B 9.35B 17.57B 1,182B 17.71B 118B 45.83B 580B 47B 46B 2,007B | 8.08B 9.37B 7.43B 6.99B 13.14B 884B 13.25B 88.07B 34.29B 434B 35.17B 34.41B 1,501B |
| Date | Price | Change |
|---|---|---|
| 17/06/26 | 37.00 € | -2.12% |
| 16/06/26 | 37.80 € | 0.00% |
| 15/06/26 | 37.80 € | -1.56% |
| 12/06/26 | 38.40 € | +0.52% |
| 11/06/26 | 38.20 € | +1.60% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SAN Stock
- SNW2 Stock
Select your edition
All financial news and data tailored to specific country editions
